Alzheimer's disease ͉ estrogen therapy ͉ risk factor regulation ͉ Alzheimer's disease prevention A polipoprotein E (ApoE) is a 34-kDa lipid binding protein that functions in the transport of triglycerides and cholesterol in multiple tissues, including brain, by interacting with lipoprotein receptors on target cells (1-4). Three ApoE isoforms exist in humans: ApoE2, ApoE3, and ApoE4, which differ from one another by single amino acid substitutions at positions 112 and 158, ApoE2 (Cys-112, Cys-158), ApoE3 (Cys-112, Arg-158), and ApoE4 (Arg-112, Arg-158) (5). Substitution of cysteine at position 158 in ApoE2 results in hypocholesterolemia caused by low levels of low-density lipoprotein (LDL), cholesterol (6). In contrast, substitution of cysteine with arginine at position 112 in ApoE4 results in elevation of plasma cholesterol and LDL levels and predisposes the carrier to cardiovascular disease and neurodegenerative disorders, including Alzheimer's disease (AD) (7, 8) .
A polipoprotein E (ApoE) is a 34-kDa lipid binding protein that functions in the transport of triglycerides and cholesterol in multiple tissues, including brain, by interacting with lipoprotein receptors on target cells (1) (2) (3) (4) . Three ApoE isoforms exist in humans: ApoE2, ApoE3, and ApoE4, which differ from one another by single amino acid substitutions at positions 112 and 158, ApoE2 (Cys-112, Cys-158), ApoE3 (Cys-112, Arg-158), and ApoE4 (Arg-112, Arg-158) (5) . Substitution of cysteine at position 158 in ApoE2 results in hypocholesterolemia caused by low levels of low-density lipoprotein (LDL), cholesterol (6) . In contrast, substitution of cysteine with arginine at position 112 in ApoE4 results in elevation of plasma cholesterol and LDL levels and predisposes the carrier to cardiovascular disease and neurodegenerative disorders, including Alzheimer's disease (AD) (7, 8) .
Statistically, individuals with one copy of the ApoE4 allele show a 4-fold increase in the risk of AD, whereas those with two copies of the ApoE4 allele exhibit a 15-fold increase in risk coupled with a significantly lower age of onset compared with AD patients carrying ApoE2͞3 alleles (9) . The ApoE4 allele itself appears to account for as much as 50% of the populationattributable AD risk in the United States (for reviews see refs. 10 and 11) . Thus, ApoE4 is considered a risk factor for late-onset AD, whereas ApoE2 and ApoE3 are associated with decreased risk of AD (10, 12, 13) .
Previous in vitro and in vivo analyses indicate that 17␤-estradiol (E 2 ) increased ApoE expression in astrocytes and microglia and in neurons (14, 15) . Further, ApoE synthesis was required for E 2 -induced neuroprotection and neurotrophism, including neurite outgrowth (16, 17) .
Recently, we discovered that in HT-22 cells ectopically transfected with full-length estrogen receptor (ER) (ER␣ or ER␤), E 2 -induced an opposite effect on ApoE expression depending on the transfected ER subtype. Based on our own data and others (17) (18) (19) , we hypothesized that ApoE expression is differentially regulated by ER subtypes. To test this hypothesis, we investigated the impact of ER␣ versus ER␤ on ApoE gene expression by using real-time RT-PCR with confirmation of protein levels by Western blot in primary cultured rat hippocampal neurons. To determine the in vivo significance of our in vitro findings, we conducted in vivo analyses in ovariectomized (OVX) female rats treated with either the ER␣-selective ligand, propylpyrazole triol (PPT) or the ER␤-selective ligand, diarylpropionitrile (DPN). Results of these analyses demonstrated that the expression of ApoE is differentially regulated by ER␣ and ER␤. Activation of ER␣ increased, whereas activation of ER␤ decreased ApoE mRNA and protein expression in vitro and in vivo in rat hippocampus.
Results

Differential ApoE Expression in HT-22 Cells Transfected with ER␣ or
ER␤. To determine the ER subtype mediating E 2 regulation of ApoE, mouse hybrid HT-22 cells were transfected with either full-length ER␣ or ER␤ and subsequently exposed to E 2 (10 ng͞ml, 37 nM). The concentration of E 2 was based on our previous findings that 10 ng͞ml was the optimal dose for activating both neuroprotective and neurotrophic actions of E 2 (20, 21) , and it was used in all in vitro tests. ApoE expression was assessed by real-time RT-PCR and Western blot. As shown in Fig. 1 , ApoE mRNA expression was readily detectable by real-time RT-PCR using specific primers as described in Materials and Methods (also see Fig. 5 , which is published as supporting information on the PNAS web site). PCR products were subjected for sequencing and confirmed generation of correct products. Efficiency of real-time RT-PCR was determined by serial dilution of cDNA. The coefficient of determination across different dilution factors was Ͼ0.93 in all of the experiments, indicating the high efficiency of the real-time RT-PCR. E 2 induced a 1.2-to 1.4-fold increase in ApoE mRNA expression in mock-transfected cells. In cells transfected with eGFP-C3 vector alone, E 2 induced a low level of E 2 -inducible ApoE expression similar to that seen for the mock-transfected cells (Fig. 1 A) . These findings are consistent with our earlier analyses that demonstrated a low-level expression of both ER␣ and ER␤ in HT-22 cells † and indicated that eGFP-C3 vector had no effect on E 2 -inducible ApoE expression. In HT-22 cells transfected with rat ER␣, E 2 induced a 3.7-fold increase in ApoE mRNA (Fig. 1 A) . In contrast, in HT-22 cells transfected with ER␤, E 2 induced a 5-fold reduction of ApoE mRNA (Fig. 1 A) . These data suggested diametrically different effects of ER␣ and ER␤ on regulation of ApoE expression.
To confirm that E2-induced ApoE mRNA expression was paralleled by changes in protein level, Western blots were performed with a specific ApoE antibody (Calbiochem, San Diego, CA). ApoE (34 kDa) protein level was consistent across each of the HT-22 cell types in the absence of E 2 , indicating that transfection with either ER␣ or ER␤ did not change the constitutive expression level of ApoE in these cells (Fig. 1B) . In agreement with mRNA levels, E 2 induced a significant 70% increase (P Ͻ 0.01 vs. vehicle control) in ApoE protein expression in HT-22 cells transfected with ER␣ (Fig.  1B) . In HT-22 cells transfected with ER␤, E 2 induced a significant 40% decrease (P Ͻ 0.01 vs. vehicle control) in ApoE protein level (Fig. 1B) .
17␤-E2 Regulation of ApoE Expression in Embryonic Day-18 Rat
Hippocampal Neurons in Primary Culture. To verify that cultured hippocampal neurons were a suitable model for this purpose, we first determined the expression of ApoE in rat hippocampal neurons in culture by double immunofluorescence labeling for ApoE and the neuronal marker microtubule-associated protein 2 (MAP2) or the glial marker glial fibrillary acidic protein (GFAP). MAP2-positive cells accounted for Ͼ99.5%, whereas Ͻ0.4% were GFAP-positive in the culture system, which is consistent with previous reports (22) (23) (24) . After 7 days in culture, MAP2-positive hippocampal neurons expressed ApoE at a readily detectable level (Fig. 6 , which is published as supporting information on the PNAS web site). ApoE-like immunoreactivity was observed in MAP2-positive neurons, the cell body and neurites, and GFAP-positive glial cells.
We subsequently determined whether ApoE expression was regulated by E 2 in rat hippocampal neurons in primary culture. Rat embryonic day 18 hippocampal neurons at 7 days in vitro were exposed to E 2 or vehicle for 24 h, and ApoE mRNA expression was determined by RT-PCR. In both control and E 2 -treated neurons, ApoE mRNA was readily detected by all three primer pairs (Fig. 2) , indicating ApoE gene expression in rat hippocampal neurons at 7 days in vitro. Further, each ApoE primer set generated a single band at the expected nucleotides position, indicating no genome DNA contamination and the specificity of the primer pairs used in the RT-PCR (Fig. 2 A) . The negative control, no-reverse transcriptase template, generated no band as seen in Fig. 2 A, indicating no genome DNA contamination. Exposure of hippocampal neurons to E 2 for 24 h resulted in a 93% (P Ͻ 0.01) greater amplification of ApoE products from each of the primer pairs (Fig. 2) . The (A) Cultured rat hippocampal neurons were treated with 10 ng͞ml (37 nM) 17␤-E 2 or vehicle for 24 h at 37°C. Total RNA was isolated, and RT-PCR was conducted by using specific primer sets to amplify rat ApoE. ␤-actin was used as a reference to evaluate equal loading. No reverse transcriptase (prepared from the same amount and same preparation of RNA but without reverse transcriptase) was used as a negative control. RT-PCR products were analyzed by ethidium bromide agarose gel electrophoresis. (B) Average intensity of ApoE PCR products derived from three different primers indicated a highly significant ( * , P Ͻ 0.01) 2-fold increase in ApoE mRNA expression relative to vehicle control.
contribution of GFAP-positive cells to ApoE expression is predicted to be minimal given the low number of glial cells relative to the preponderance of neurons in the culture system.
ER Isoform-Specific Ligands, DPN and PPT, Differentially Regulate in Vitro Expression of ApoE in Primary Cultured Hippocampal Neurons.
Both ER␣ and ER␤ are expressed in embryonic day 18 rat primary cultured hippocampal neurons (20, 21) . To determine the function of endogenously expressed ER␣ and ER␤ on regulation of ApoE expression, we conducted analyses of ApoE protein expression in primary rat hippocampal neurons exposed to either E 2 (10 ng͞ml), the ER␣-specific ligand PPT (0.5 nM), or the ER␤-selective ligand DPN (0.3 nM) for 24 h. Concentrations of ligands were based on our prior dose-response analyses that indicated that these concentrations of E2, PPT, or DPN were the EC 100 required to induce maximal neuroprotection (25) . Results of these analyses indicated that hippocampal neurons exposed to E 2 increased ApoE protein levels by 23% (P Ͻ 0.05; see Fig. 3 ), and the ER␣-specific ligand PPT induced a significant 57% increase in ApoE protein expression (P Ͻ 0.01; Fig. 3 ). In contrast, the ER␤-selective agonist DPN induced a 28% reduction in hippocampal neuron ApoE protein expression (P Ͻ 0.05; Fig. 3 ). These data are consistent with results of analyses from ER␣-and ER␤-transfected HT-22 cells and further indicate the mixed induction͞repression properties of the nonselective ER␣ and ER␤ ligand E 2 .
ER Isoform-Specific Ligands, DPN and PPT, Differentially Regulate the in Vivo Expression of ApoE in Rat Hippocampi. To confirm that our in vitro analyses accurately reflected outcomes in vivo, 4-to 6-month-old OVX rats were injected with E 2 (30 g͞kg), PPT (30 g͞kg), or DPN (100 g͞kg). Female rats were OVX 14 days before exposure to either E 2 , PPT, or DPN. Doses of E 2 , PPT, and DPN used for in vivo analyses were based on three considerations. First, Struble et al. (17) and Stone et al. (14) reported that ApoE expression changed in rodent hippocampus during the estrus cycle and was significantly higher during proestrous, when E 2 levels were highest (Ϸ40 pg͞ml). Second, our analysis of E 2 plasma and brain levels after a 30-g͞kg dose produced levels in OVX rats of 42 pg͞g E 2 in brain tissue and 44 pg͞ml E 2 in serum (data not shown), which is comparable to proestrus levels. Third, the 30-g͞kg dose of PPT was found to be as effective as 100 g͞kg in promoting mitochondrial respiration in vivo, whereas 100 g͞kg DPN was required to induce maximal response ‡ . Rat hippocampi were dissected 24 h after treatment followed by RNA and protein extraction. ApoE expression was evaluated by real-time RT-PCR and Western blot after enrichment by immunoprecipitation from 200 g of total protein extract. As shown in Fig. 4A , E 2 and the ER␣-selective agonist PPT induced a 2.5-and 3-fold increase, respectively, in ApoE mRNA expression. In contrast, the ER␤-selective agonist DPN induced the opposite effect, a 4-fold decrease (Fig. 4A) . 3 . ER-selective ligands differentially regulate ApoE expression in rat hippocampal neurons in primary culture. Hippocampal neurons were treated with either 10 ng͞ml (37 nM) 17␤-estradiol, 0.3 nM DPN-specific agonist to activate ER␤, or 0.5 nM PPT to activate ER␣ for 24 h. Protein (40 g) derived from the total cell lysates was loaded in each lane, and Western blots were performed by using ApoE antibody and visualized by the peroxidase-3,3Ј,5,5Ј-tetramethylbenzidine. Protein band intensity was quantitatively normalized by loading control ␤-actin and statistically analyzed by two-way ANOVA. Consistent with the mRNA data, activation of ER␣ induced a significant increase in ApoE, whereas activation of ER␤ induced a significant decrease in ApoE. Data are presented as mean Ϯ SEM from three independent experiments. * , P Ͻ 0.05. (B) A representative Western blot image shows ApoE protein levels in rat hippocampus after different treatments. The equal amounts of IgG heavy and light chains indicate that equal amounts of ApoE antibodies were used for immunoprecicpitation and that equal loading of protein occurred. The human high-density lipoprotein (HDL), which contains a high amount of ApoE, was used as a positive control. In the HDL lane, the lower band presents the 34-kDa ApoE, and the upper band depicts the SDS stable ApoE͞A␤ complex (63) . (C) Summary of the Western blot data from at least three rats in each group. E 2 induced a 51% increase in ApoE protein expression and PPT induced a 85% increase. In contrast, DPN abolished ApoE protein expression. Data are mean Ϯ SEM. ** , P Ͻ 0.01; * , Ͻ 0.05 vs. control).
heavy and light chain in each sample indicates the equal amount of ApoE antibody used during immunoprecipitation and also serves as a control to indicate equal protein loading. E 2 and ER␣ agonist PPT treatments induced a 51 Ϯ 17 and 85 Ϯ 10% increase, respectively, in ApoE protein expression. In contrast, the ER␤ selective agonist DPN induced a complete abolition of ApoE expression (Fig. 4C ) (n Ն 3 in each group). One-way ANOVA and the post hoc t test analysis indicated significant differences between E2, PPT, and DPN vs. vehicle (P ϭ 0.017, 0.003, and 0.001, respectively) (Fig. 4C) .
Discussion
Our results demonstrated that E 2 increased ApoE mRNA and protein levels. These findings are consistent with previous reports of Finch and colleagues (15) who demonstrated that E 2 increased ApoE in cells isolated from CNS and by other investigators in vivo (16) (17) (18) . In this study, we demonstrated that ApoE expression is differentially regulated by ER␣ and ER␤. Activation of ER␣ increased, whereas activation of ER␤ decreased expression of ApoE in rat hippocampal neurons.
ApoE Expression in Rat Hippocampal͞Hippocampal
Neurons. Brain levels of ApoE are very high and are second only to that in liver (26) . In brain, early studies demonstrated that ApoE is primarily synthesized by glial cells and ependymal layer cells, but not by neurons (27, 28) . However, subsequent analyses provided evidence for neuronal expression of ApoE immunoreactivity in cortical and hippocampal neurons of AD patients and aged control subjects (13, 29, 30) . In our analyses, we used primary hippocampal neuron cultures that are Ͼ99% neuronal and Ͻ0.4% glial (24) and confirmed ApoE expression in both neurons and glia by immunocytochemistry .
E2-Regulated ApoE Expression Is Mediated by ER and Is ER Isoform-
Specific. Several groups have demonstrated that estrogen regulates ApoE expression (14) (15) (16) (17) . In vivo verification of in vitro E 2 regulation of ApoE was demonstrated in the study by Struble et al. (17) . Importantly, this study demonstrated that in vivo ApoE level was maximally elevated when E 2 levels were highest during the estrous cycle in a brain region-specific manner (17) . ApoE expression levels were two to six times higher in hippocampus and cortex during proestrous, when E2 levels are high, relative to estrus (31) . Remarkably, in two brain regions that primarily express ER␤, olfactory bulb and cerebellum, ApoE levels were at least 2-fold lower during proestrus than estrus (17) . Our data that ER␣ increased and ER␤ decreased ApoE expression are entirely consistent with these in vivo data of Struble et al. Moreover, and most importantly, their findings provide a physiologically meaningful in vivo correlate to our in vivo pharmacological findings that ER␣ increased and ER␤ decreased ApoE expression in OVX female rat hippocampus. Our findings coupled with those of Struble et al. are particularly relevant to the clinical data indicating a relationship between ER, ApoE4, and AD (32) (33) (34) and strongly suggest ER isoform-specific ligands could be important therapeutic alternatives for AD prevention.
Both ER␣ and ER␤ are expressed in hippocampus and cortex of rodent and human brain (36) (37) (38) (39) , and activation of either ER isoform can promote neuron survival in cultured hippocampal neurons (25) . Gustafsson and coworkers (39) proposed a yin͞ yang relationship in which ER␤ antagonizes ER␣ action. Results of our analyses support this proposition as ER␣ and ER␤ had opposite effects on ApoE induction and the ER␣͞ER␤ agonist E 2 induced an ApoE level intermediate between that induced by selective agonists for ER␣ and ER␤. Although parallel examples of such ER-dependent differential regulation on other gene expression in hippocampus remain to be developed, different effects of ER isoforms have been reported in endothelial cells and brain hypothalamus. For example, ER␤ but not ER␣ regulated corticotropin-releasing hormone promoter activity (40) . In contrast, activation of ER␣ but not ER␤ increased progesterone receptor expression in the developing rat brain (41) . In aortic endothelial cells, ER␣ increased plasminogen activator inhibitor (PAI-1) promoter activity by an estrogendependent mechanism, whereas ER␤ suppressed PAI-1 promoter activity by an estrogen-independent mechanism (31). In addition, variants of ER␤ (34) or the polymorphisms of ER␣ (33) may alter ApoE expression, although mechanisms underlying these effects remain to be established. Collectively, these data are consistent with ER isoforms differentially regulating protein expression.
In addition to differential outcomes determined by ER isoform, ApoE genotype can determine outcomes of E 2 exposure. In the absence of ApoE, estrogen did not show any effect on neurite sprouting (42, 43) . Nathan et al. (16) found that E 2 -induced neurite sprouting depended on the ApoE genotype. ApoE4 inhibited, whereas ApoE3 enhanced, neurite outgrowth in a dose-dependent manner (44, 45) . Inhibition of neurite sprouting was caused by the presence of ApoE4, but not the absence of ApoE3 (4). E 2 had no effect on neurite outgrowth in neuron cultures from mice lacking the ApoE gene or mice transgenic for human ApoE4. In contrast, E 2 significantly increased neurite growth of neurons in culture from mice transgenic for human ApoE3 (16) . Although the ApoE2͞3 and ApoE4 genotypes responded differently to E 2 -induced neuritic sprouting, E 2 induced an increase in ApoE expression regardless of genotype (16) .
In rodents there is only one ApoE isoform (Arg-112, Arg-158) (46) . Importantly, this ApoE isoform is similar to human ApoE4 with arginines at positions 112 and 158 (13) . However, unlike human ApoE4, rat ApoE contains Thr-61, not Arg-61 as in human ApoE. In human ApoE4, Arg-61 is critical for the interaction with Glu-255 that leads to the compact structure of human ApoE4. Thus rat ApoE does not form a compact structure as human ApoE4 isoform does (13) . Three major ApoE isoforms are expressed in humans: ApoE2 (Cys-112, Cys-158), ApoE3 (Cys-112, Arg-158), and ApoE4 (Arg-112, Arg-158) (47) . These polymorphisms locate at the coding region, exon4 (11) . Because all three alleles are at a single gene locus, ApoE alleles are transcriptionally regulated by the same promoter. In addition, the demonstration that there is no allelic imbalance in brain ApoE3͞4 expression in AD patients and age-matched controls who are ApoE3͞4 heterozygous excluded the possibility that these polymorphisms might contribute to ApoE gene transcription (48) .
ER, ApoE, and AD. There appears to be a gender bias in the risk of AD with women exhibiting a greater risk when compared with age-matched males (49) . A meta analysis of 40 studies of ApoE genotype, sex, age of onset of AD, and ethnic background for 5,930 patients and 8,607 controls indicated that at most ages and across all genotypes women are more likely to develop AD (50) . Moreover, the presence of one or more ApoE4 alleles conferred a substantially greater risk of AD to women than to men (51) . Epidemiological data indicate that women are particularly susceptible to the adverse effects of a single copy of ApoE4 isoform in that women with the ApoE3͞4 allele had the same risk of AD as the women with the ApoE4͞4 allele (50, 52, 53) . A direct comparison of E4 heterozygous men and women revealed a significant 2-fold increased risk of AD in women (52) .
In a neurologically normal cohort of postmenopausal women, a cross-sectional analysis of the interaction between ApoE genotype and estrogen therapy (ET) indicated that the highest level of learning and memory occurred in women receiving ET and who were not ApoE4 carriers (54) . ET had no effect on performance of ApoE 4 carriers as they performed at the same level as ApoE 4 carriers not receiving ET (54). Yaffe et al. (55) found that among ApoE4-negative women, current estrogen use reduced the risk of cognitive impairment compared with never users by almost half, whereas it did not reduce the risk among ApoE4-positive women. Women who were not ApoE4 carriers and received ET͞hormone therapy (HT) had the highest level of cognitive performance, whereas women who were ApoE4 carriers and received ET͞HT performed worse than ApoE4 carriers not receiving ET͞HT (55, 56) . These data suggest that the ApoE allele is a major determinant of ET͞HT efficacy for cognition and can at least partially explain the complex results derived from the ET͞HT clinical trials, as current ET formulations would increase ApoE expression irrespective of allelic type. Differential regulation of ApoE expression by selective activation of ER␣ and ER␤ and the mixed ER␣͞ER␤ agonist properties of E 2 suggest that, in a heterogeneous population, outcomes of ET͞HT could be partially determined by the ApoE2͞3 and ApoE4 allele.
An increasing body of evidence, including the current analyses, suggests that activation of the ER isoform is a critical consideration and indicates that estrogen action in brain is particularly relevant to cognitive function and risk of AD. Swaab's group (35, 57) has demonstrated that ER␣ expression is increased in the AD patient and aged control brains, particularly in those positive for ApoE4 allele (58) . This observation suggests at least a correlative relationship between ER␣, ApoE isoforms, and either risk or progression of AD or both. ER␤ levels did not change in AD and aged men, but decreased in aged women (35, 57, 58) . Recently, SNPs in the first intron of ER␣ were highly correlated with incidence of AD, particularly sporadic AD, development (32, (59) (60) (61) (62) . Furthermore, intronic SNPs in the ER␤ gene were associated with a Ϸ2-fold increase in the risk of AD in women, whereas polymorphisms did not contribute to the AD susceptibility in men (34) . Although it is still not clear how these SNPs affect ER function and increase risk of AD, these findings provide strong support for the relationship between ER isoform and AD development.
These findings together with our current discovery that ER␣ increased whereas ER␤ decreased ApoE expression leads to the following hypothesis: In aged women an increase of ER␣ combined with ET͞HT will increase ApoE, which in ApoE4 heterozygotes and homozygotes will increase risk and or progression of AD. In parallel, a decrease in ER␤ in aged women would reduce the inhibitory effect of ER␤ on ApoE expression and as a result lead to an increase in ApoE, including ApoE4. In conclusion, results of our analyses, coupled with the data on ApoE allele phenotype and risk of AD in women, would predict that women with an ApoE2͞3 allelic variation could benefit from ET selective for the ER␣ subtype in brain or a mixed ER␣͞ER␤ agonist formulation. Conversely, women expressing the ApoE4 allele, either heterozygotes or homozygotes could benefit from an ER␤-selective therapy.
Materials and Methods
Animals and Treatment. All studies were approved by the University of Southern California Institutional Review Board for animal care. All experiments conformed to the Animal Welfare Act, Guide to Use and Care of Laboratory Animals, and the U.S. Government Principles of the Utilization and Care of Vertebrate Animals Used in Testing, Research, and Training guidelines on the ethical use of animals. In addition, the minimal number of required animals was used for these experiments and suffering was minimized.
Four-to 6-month-old female Sprague-Dawley rats (Harlan, Indianapolis, IN) were OVX and 14 days after ovariectomy were s.c.-injected (14 days after OVX) with vehicle (n ϭ 6), E2 (30 g͞kg, n ϭ 6), PPT (30 g͞kg, n ϭ 3), or DPN (100 g͞kg, n ϭ 3) for 24 h. The 14-day time interval between ovariectomy and treatment was selected to ensure maximal clearance of residual E 2 from the circulation and presumably tissue. The hippocampi were sampled and flash-frozen in liquid nitrogen. Uterine wet weight was recorded to verify the hyperproliferative cell response to estrogens. The samples were subjected for RNA and protein extraction as described (24) .
The expression of ApoE mRNA was detected by real-time RT-PCR using primers as described in Supporting Text, which is published as supporting information on the PNAS web site.. The protein samples were then subjected to Western blot as described in Supporting Text.
